Penn Medicine Provider
Medical Oncology
Lynn M. Schuchter, MD
5.0
(521)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Valley Forge
View 1 additional location

About me

  • Director, Tara Miller Melanoma Center
  • Madlyn and Leonard Abramson Professor of Clinical Oncology

Education and training

  • Medical School: Chicago Medical School
  • Residency: Michael Reese Hospital
  • Fellowship: Johns Hopkins Hospital
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

521 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
she's the best!
May 2025
5.0
5.0
did a great job
April 2025
5.0
5.0
the best dr.
April 2025
5.0
5.0
overall, professional but needs to become better with time management

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Schuchter is a Penn Medicine physician.

Qualifications and experience

My research

Sargen MR, Barnhill RL, Elder DE, Swetter SM, Prieto VG, Ko JS, Bahrami A, Gerami P, Karunamurthy A, Pappo AS, Schuchter LM, LeBoit PE, Yeh I, Kirkwood JM, Jen M, Dunkel IJ, Durham MM, Christison-Lagay ER, Austin MT, Aldrink JH, Mehrhoff C, Hawryluk EB, Chu EY, Busam KJ, Sondak V, Messina J, Puig S, Colebatch AJ, Coughlin CC, Berrebi KG, Laetsch TW, Mitchell SG, Seynnaeve B.J Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. , Clin Oncol.: 2024


Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X. Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival. , Clin Cancer Res: 2024


Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. , Cancer Cell: 2024


Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812] , Ann Oncol: 2024


Takvorian SU, Gabriel P, Wileyto EP, Blumenthal D, Tejada S, Clifton ABW, Asch DA, Buttenheim AM, Rendle KA, Shelton RC, Chaiyachati KH, Fayanju OM, Ware S, Schuchter LM, Kumar P, Salam T, Lieberman A, Ragusano D, Bauer AM, Scott CA, Shulman LN, Schnoll R, Beidas RS, Bekelman JE, Parikh RB Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk: A Cluster Randomized Trial. , JAMA Network Open: 2024


Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. , Clin Cancer Res: 2024


Ravi B Parikh, Emily Schriver, William J Ferrell, Jonathan Wakim, Joelle Williamson, Neda Khan, Michael Kopinsky, Mohan Balachandran, Peter E Gabriel, Lynn M Schuchter, Mitesh S Patel, Lawrence N Shulman, Christopher R Manz Remote Patient-Reported Outcomes and Activity Monitoring to Improve Patient-Clinician Communication Regarding Symptoms and Functional Status: A Randomized Controlled Trial , JCO Oncol Pract: 2023


Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity , Cell Rep. : 2023


Sarah A Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz-Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M Schuchter, Maria Gonzalez Cao, Ana Arance Fernandez, Wei Wei, Apar Kishor Ganti, Ralph J Hauke, Alfonso Berrocal, Nicholas O Iannotti, Frank J Hsu, Harriet M Kluge A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1 , Clin Cancer Res : 2023


Lingling Ou, Shujing Liu, Huaishan Wang, Yeye Guo, Lei Guan, Longbin Shen, Ruhui Luo, David E Elder, Alexander C Huang, Giorgos Karakousis, John Miura, Tara Mitchell, Lynn Schuchter, Ravi Amaravadi, Ahron Flowers, Haiwei Mou, Fan Yi, Wei Guo, Jina Ko, Qing Chen, Bin Tian, Meenhard Herlyn, Xiaowei Xu Patient-derived melanoma organoid models facilitate the assessment of immunotherapies , EBioMedicine: 2023